ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

INSM Insmed Inc

25.55
-0.11 (-0.43%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Insmed Inc NASDAQ:INSM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.11 -0.43% 25.55 25.10 26.69 26.43 25.40 26.23 1,259,050 22:30:00

Insmed to Present at Three September Conferences

09/09/2020 9:05pm

PR Newswire (US)


Insmed (NASDAQ:INSM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Insmed Charts.

BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences:

  • The H.C. Wainwright Annual Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET
     
  • The Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15, 2020 at 9:30 a.m. ET
     
  • The Cantor Virtual Healthcare Conference on Thursday, September 17, 2020 at 9:20 a.m. ET

Each presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed is also advancing brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com 

Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

(PRNewsfoto/Insmed Incorporated)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-three-september-conferences-301126868.html

SOURCE Insmed Incorporated

Copyright 2020 PR Newswire

1 Year Insmed Chart

1 Year Insmed Chart

1 Month Insmed Chart

1 Month Insmed Chart

Your Recent History

Delayed Upgrade Clock